Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Jurgis Bekepuris who wrote (38151)	6/12/2010 2:20:58 PM
From: Jurgis Bekepuris	Read Replies (2) \| Respond to of 78594

My top 10-ish positions in no particular order: IGK/ISF/IDG, NRF-A/B, UVIC, GPOR, FR-J, EBIX, AEH, COPJF, CSGH, GILD, RINO, UEPS. No changes in this list since last time. New positions: AMGN Positions increased: DRAGF, UVIC, COPJF, IDCC, CF, HRBN, FCX, GILD, CBEH Positions reduced: CF Positions eliminated: None I bought an exploratory position in AMGN, but after more research I am not sure if I will increase it. Their success in getting denosumab/Prolia approved does not cover the issue (IMHO) that they have increasing biogeneric competition and a number of patent expirations in their largest selling drugs in 2010-2015 time frame. IMHO, GILD is more attractive than AMGN. CF is another one where I am not sure that the position is warranted at the current price. I may just hold my current stake and reevaluate when it is clearer how their Terra acquisition integration proceeds.